Prezista franchise
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson), as well as the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU. Prezista is a once-daily, boosted PI for the treatment of HIV-1 infection in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Tybost is a boosting agent to be used in combination with PIs as part of treatment regimens for HIV-1 infection. PIs block the activity of the HIV-1 protease enzyme, which inhibits cleavage of the Gag-Pol polyprotein precursor. This results in the production of an immature, non-infectious virus.
While Prezista and Prezcobix are expected to continue to absorb patient share from rival PIs, Datamonitor Healthcare expects sales of the franchise to decline due to physician preference for the plethora of novel integrase strand transfer inhibitor-based regimens in the early lines of therapy, as well as the imminent threat of generic erosion. Indeed, the availability of generic atazanavir, and of generic darunavir from June 2019, are expected to trigger a substantial decline in revenues from the Prezista franchise as payers seek to capitalize on the savings offered by cheaper generics.
Analyst Outlook
While Prezista (darunavir; Johnson & Johnson) and Prezcobix ([darunavir + cobicistat]; Johnson & Johnson/Gilead) are expected to continue to absorb patient share from rival protease inhibitors (PIs), Datamonitor Healthcare expects sales of the franchise to decline due to physician preference for the plethora of novel integrase strand transfer inhibitor (INSTI)-based regimens in the early lines of therapy, as well as the imminent threat of generic erosion. Indeed, the availability of generic atazanavir, and of generic darunavir from June 2019, are expected to trigger a substantial decline in revenues from the Prezista franchise as payers seek to capitalize on the savings offered by cheaper generics.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Prezista franchise : HIV
LIST OF FIGURES
14 Figure 45: Tivicay sales for HIV across the US and five major EU markets, by country, 2018–27
15 Figure 46: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
18 Figure 47: Datamonitor Healthcare’s drug assessment summary of Triumeq for HIV
19 Figure 48: Triumeq sales for HIV across the US and five major EU markets, by country, 2018–27
LIST OF TABLES
5 Table 1: Prezista drug profile
6 Table 2: Prezcobix drug profile
7 Table 3: Approval history of Prezista for HIV in the US, Japan, and five major EU markets
9 Table 4: Late-phase trials of Prezista for HIV
11 Table 5: Approval history of Prezcobix for HIV in the US, Japan, and five major EU markets
12 Table 6: Late-phase trials of Prezcobix for HIV
13 Table 7: Prezista franchise for HIV – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Stribild 
Sign up to the